47 completed, 6 unknown, 5 withdrawn, 2 terminated. 42 Phase 1, 16 Phase 2, 6 Not applicable, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 42 | Completed 35, Withdrawn 4, Unknown 3 |
| Phase 2 | 16 | Completed 14, Unknown 2 |
| Not applicable | 6 | Completed 3, Unknown 3 |
| Phase 3 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
Follow Aluminum Hydroxide: new trials by email Literature Review of Aluminum Hydroxide trials Research Report on Aluminum Hydroxide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702) - HIV | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-07 | 2025-03-26 | |
| MSP3-CRM-Vac4All/ Alhydrogel® Vaccine MSP3-CRM-Vac4All/ Alhydrogel®, Anti-Rabies Vaccine - Malaria,Falciparum | Phase 1 / Phase 2 | Unknown | Vac4All | 465 | 2023-03-27 | 2023-04-26 |
| KLH Challenge to Explore the Human Immune Response Keyhole-Limpet Hemocyanin, Saline, Montanide ISA 51 VG - Immune Response | Not applicable | Unknown | University of Oxford | 39 | 2023-03-01 | 2023-05-25 |
| Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above Medium-dosage COVID-19 Vaccine,Inactivated, High-dosage COVID-19 Vaccine,Inactivated, Placebo-comparator group - COVID-19 | Phase 3 | Withdrawn | Sinovac Research and Development Co., Ltd. | 2023-02-20 | 2023-02-08 | |
| A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system, GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system - Hepatitis B | Phase 1 | Completed | GlaxoSmithKline | 122 | 2022-10-04 | 2026-01-15 |
| A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo - Type 1 Diabetes Mellitus | Phase 3 | Terminated | Diamyd Medical AB | 321 | 2022-05-19 | 2026-08-26 |
| MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine MSP3-CRM-Vac4All/ Alhydrogel® - Malaria,Falciparum | Phase 1 | Unknown | Vac4All | 42 | 2021-12-01 | 2023-02-28 |
| Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant - HIV Infections | Phase 1 | Completed | Madhu Chhanda Choudhary | 32 | 2021-09-30 | 2026-01-22 |
| A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a Injection SF2A-TT15 10 µg Adjuvanted, Injection SF2A-TT15 10 µg, Injection Adjuvanted Placebo - Healthy | Phase 2 | Completed | Institut Pasteur | 248 | 2020-10-06 | 2024-04-23 |
| Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects Tebipenem pivoxil hydrobromide (TBPM-PI-HBr), 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL), Omeprazole - Healthy Volunteers | Phase 1 | Completed | Spero Therapeutics | 20 | 2020-07-01 | 2020-09-04 |
| SCB-2019 as COVID-19 Vaccine SCB-2019, SCB-2019 with AS03 adjuvant, SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant - COVID-19 | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 166 | 2020-06-19 | 2022-02-18 |
| Occlusion vs Standard Treatment for the Treatment of Herpes Zoster Aluminum sulphate and calcium acetate drying soaks, Topical sterile silicone gel for wounds, Hydrocolloid dressing - Herpes Zoster | Not applicable | Unknown | Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. | 36 | 2020-02-26 | 2020-02-28 |
| Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults VRC-HIVRGP096-00-VP, Alum Adjuvant - Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 16 | 2019-03-07 | 2021-08-12 |
| Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted PAMVAC, Alhydrogel, GLA-SE - Malaria, Antepartum | Phase 1 | Completed | University Hospital Tuebingen | 66 | 2016-05-01 | 2018-06-26 |
| Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults PRIMVAC, GLA-SE, Alhydrogel - Malaria | Phase 1 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 68 | 2016-01-01 | 2025-12-04 |
| Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005) V180, Alhydrogel™, Placebo - Dengue | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2015-04-01 | 2016-04-04 |
| TDENV PIV and LAV Dengue Prime-boost Strategy TDENV-LAV, TDENV-PIV 4 µg + alum adjuvant - Dengue | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 80 | 2014-12-01 | 2018-08-15 |
| Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea Capsule-Conjugate Campylobacter Vaccine (CJCV1), Alhydrogel®, aluminum hydroxide adjuvant (alum) - Campylobacter Infection | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 48 | 2014-04-21 | 2018-02-23 |
| Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults Group A1 : 50µg AMA1-DiCo + Alhydrogel, Group A2 : 50 µg AMA1-DiCo+ GLA-SE, Group B2 : Placebo - Malaria, Falciparum | Phase 1 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 66 | 2014-01-01 | 2025-12-04 |
| Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults. Low dose of H7 VLP vaccine + Alhydrogel, Med dose of H7 VLP vaccine + Alhydrogel, High dose of H7 VLP vaccine + Alhydrogel - Virus Diseases, RNA Virus Infections | Phase 1 | Completed | Medicago | 100 | 2013-12-01 | 2015-09-25 |
Showing 20 of 60. Sign in to see all of them.
HIV Infections (11) · Influenza, Human (6) · Dengue (5) · Malaria (5) · Malaria, Falciparum (5) · Autoimmune Diseases (3) · Diabetes Mellitus, Type 1 (3) · Severe Dengue (3) · Acquired Immunodeficiency Syndrome (2) · COVID-19 (2) · Coronavirus Infections (2) · Diabetes Mellitus (2) · Hepatitis B (2) · Infections (2) · Influenza in Birds (2)
National Institute of Allergy and Infectious Diseases (NIAID) (20) · U.S. Army Medical Research and Development Command (4) · Diamyd Therapeutics AB (2) · Institut National de la Santé Et de la Recherche Médicale, France (2) · Medicago (2) · Radboud University Medical Center (2) · Vac4All (2) · Alexey Mukhin (1) · Clover Biopharmaceuticals AUS Pty (1) · Diamyd Medical AB (1) · El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (1) · Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. (1) · GlaxoSmithKline (1) · Hawaii Biotech, Inc. (1) · Institut Pasteur (1)
United States (31) · United Kingdom (4) · Canada (3) · Germany (3) · Mali (3) · Netherlands (3) · Sweden (3) · Australia (2) · Burkina Faso (2) · France (2) · Mexico (2) · Austria (1) · Belgium (1) · Benin (1) · China (1)
McElrath J (3) · Odile Launay, Professor (2) · Alexey G Mukhin, M.D., Ph.D. (1) · Andre Knottnerus, MD, PhD (1) · Anna Durbin, MD (1) · Armelle Phalipon, PhD (1) · Beth-Ann Coller, PhD (1) · Carl-David Agardh, MD, phD (1) · Christiane Gerke, PhD (1) · Clemente Diaz, MD (1) · D Schwartz (1) · David Melnick, M.D. (1) · Diane Wherrett, M.D. (1)
PMID 33717176, PMID 18253503, PMID 18260764, PMID 18808338, PMID 18843118, PMID 19150702, PMID 19577636, PMID 19773098, PMID 20921313, PMID 21116604, PMID 21714999, PMID 23056238, PMID 24302596, PMID 24625805, PMID 26458804, PMID 27707765, PMID 28081133, PMID 28719287, PMID 28947345, PMID 29512481, PMID 30629148, PMID 30885725, PMID 32032566, PMID 32394880, PMID 32966573, PMID 33524311, PMID 34611164, PMID 35783486, PMID 36316084, PMID 40576086, PMID 42617627
2009 (1), 2015 (1), U01AI152969 (1), U01DK061055 (1), UC4DK097835 (1)